VEENAT 400 MG

About

VEENAT 400 MG, containing Imatinib, is a potent tyrosine kinase inhibitor designed to target specific proteins involved in cancer cell growth. It primarily acts by inhibiting the Bcr-Abl tyrosine kinase, a hallmark of chronic myeloid leukemia (CML), and the KIT receptor tyrosine kinase, which is crucial in gastrointestinal stromal tumors (GIST). This targeted mechanism helps to prevent the proliferation of cancer cells and induce apoptosis, thereby controlling disease progression. Imatinib has revolutionized the treatment landscape for these specific malignancies, offering a more effective and less toxic alternative to traditional chemotherapy.

Its efficacy stems from its ability to selectively block the signaling pathways that drive uncontrolled cell growth in these cancers, while largely sparing healthy cells. This selectivity contributes to its generally manageable side effect profile compared to conventional cytotoxic agents. Regular monitoring of blood counts and liver function is essential during treatment to ensure safety and optimize therapeutic outcomes.

Uses

• Treatment of chronic myeloid leukemia (CML) in various phases.
• Management of unresectable and/or metastatic gastrointestinal stromal tumors (GIST).
• Therapy for myelodysplastic/myeloproliferative diseases (MDS/MPD).
• Treatment of hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL).

Directions For Use

Take orally once daily with food and a large glass of water. Do not crush or chew the tablet.

Benefits

• Highly effective in specific types of cancer.
• Significantly improves patient survival rates.
• Offers a targeted therapy approach.
• Convenient oral administration.
• Reduces tumor burden and disease progression.
• Generally well-tolerated compared to chemotherapy.

Side Effects

• Nausea
• Vomiting
• Diarrhea
• Muscle cramps
• Fluid retention (edema)
• Fatigue
• Skin rash
• Headache
• Abdominal pain
• Neutropenia (low white blood cells)
• Thrombocytopenia (low platelets)
• Elevated liver enzymes

Safety Measures

• Alcohol - Avoid or limit alcohol consumption due to the potential for increased liver toxicity and gastrointestinal irritation while on this medication.
• Pregnancy - Not recommended during pregnancy as it can cause fetal harm. Women of childbearing potential must use effective contraception during treatment and for a period after.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if Imatinib is excreted in breast milk, posing a potential risk of serious adverse effects to the infant.
• Liver - Use with caution in patients with liver impairment. Liver function should be monitored closely, and dose adjustments may be necessary in severe cases.
• Kidney - Use with caution in patients with kidney impairment. Dose adjustments may be required, especially in severe renal dysfunction.
• Lung - Rare cases of interstitial lung disease or pneumonitis have been reported. Monitor for new or worsening respiratory symptoms such as cough or shortness of breath.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.